Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro

British Journal of Pharmacology

Volumn 123, Issue 3, 1998, Pages 590-598

  Capra, Valérie ^a   Bolla, Manlio ^a   Belloni, Pier Angelo ^b   Mezzetti, Maurizio ^c   Folco, G Carlo ^a   Nicosia, Simonetta ^a   Rovati, G Enrico ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Antagonist; Binding; CGP 45715A; CGP 57698; Cys leukotriene; Human bronchi; Human lung parenchyma; Iralukast; LTD4; Receptor

Indexed keywords

2,2 DIETHYL 4 [3 (7 FLUORO 2 QUINOLINYLMETHOXY)ANILINO] 4 OXOBUTYRIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN E ANTIBODY; IRALUKAST; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE; PRANLUKAST; RECEPTOR; UNCLASSIFIED DRUG; ZAFIRLUKAST;

AIRWAY; ARTICLE; ASTHMA; BRONCHOSPASM; CAPILLARY PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; EOSINOPHIL; EXTRAVASATION; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; MUCUS SECRETION; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANTIGENS; BENZOPYRANS; BINDING, COMPETITIVE; BRONCHI; HUMANS; LEUKOTRIENE D4; LUNG; MUSCLE CONTRACTION;

EID: 0031965149     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701636     Document Type: Article

References (45)

1. 4 binding to guinea pig lung receptors by the novel leukotriene antagonist ICI 198,615. J. Pharmacol. Exp. Ther., 243, 921-926.
2. ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative use of drug antagonists. Br. J. Pharmacol. Chemother., 14, 48-58.
3. BOLLA, M., CARUSO, P., GIOSSI M., FOLCO, G.C., CIVELLI, M. & SALA, A. (1997). Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor. Biochem. Pharmacol., 54, 437-442.
4. BRAY, M.A., ANDERSON, W.H., SUBRAMANIAN, N., NIEDERHAUSER, U., KUHN, M., ERARD, M. & VON SPRECHER, A. (1990). CGP45715A: a leukotriene D4 analogue with potent peptido-LT antagonist activity. In: Advances Prostaglandin Thromboxane Leukotriene Research, ed. Samuelsson, B., Ramwell, P.W., Paoletti, R., Folco, G.C., Granström, E. & Nicosia, S., Vol. 21, pp. 503-507. New York: Raven Press.
5. BROOKS, C.D.W. & SUMMERS, J.B. (1996). Modulators of leukotriene biosynthesis and receptor activation. J. Med. Chem., 39, 2629-2654.
6. 4 receptor. Trends Pharmacol. Sci., 10, 103-107.
7. DAHLÉN, S.E., BIÖRK, J., HEDQVIST, P., ARFORS, K.E., HAMMARSTRÖM, S., LINDGREN, J.A. & SAMUELSSON, B. (1981). Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. U.S.A., 78, 3887-3891.
8. 4. Proc. Natl. Acad. Sci. U.S.A., 80, 1712-1716.
9. DAHLÉN, S.E., HEDQVIST, P., HAMMARSTRÖM, S. & SAMUELSSON, B. (1980). Leukotrienes are potent constrictors of human bronchi. Nature, 288, 484-486.
10. DE LEAN, A., MUNSON, P.J. & RODBARD, D. (1978). Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol., 235, E97-E102.
11. DE LEAN, A., STADEL, J.M. & LEFKOWITZ, R.J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem., 255, 7108-7117.
12. DRAPER, N.R. & SMITH, H. (1966). Applied Regression Analysis. New York: Wiley.
13. DRAZEN, J.M. & AUSTEN, K.F. (1987). Leukotrienes and airway responses. Am. Rev. Respir. Dis., 135, 333-337.
14. 4 biosynthesis during polymorphonuclear leukocyte-vascular cell interactions. In Methods in Enzymology, ed Murphy, R.C. & Fitzpatrick, F.A. Vol. 187, pp. 559-567, San Diego: Academic Press, Inc.
15. 4 synthesized by polimorphonuclear leukocytes. J. Biol. Chem., 261, 16466-16472.
16. FOSTER, A. & CHAN, C. (1991). Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the activity sensitized guinea pig. Int. Arch. Allergy Immunol., 96, 279-284.
17. HAY, D.,TORPHY, T.J. & UNDEM, B.J. (1995). Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol. Sci., 16, 304-309.
18. LEFKOWITZ, R.J., COTECCHIA, S., SAMAMA, P. & COSTA, T. (1993). Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci., 14, 303-307.
19. 4 receptors in adult and fetal human lung. Biochem. Pharmacol., 34, 4311-4317.
20. LEWIS, R.A. & ROBIN, J.L. (1985). Arachidonic acid derivatives and mediators of asthma. J. Allergy Clin. Immunol., 76, 259-264.
21. 4 by human platelets. J. Biol. Chem., 263, 174-181.
22. MACLOUF, J., MURPHY, R.C. & HENSON, P. (1989). Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells. Blood, 74, 703-707
23. 4 receptor in guinea pig lung. J. Biol. Chem., 268, 6487-6495.
24. MILLIGAN, G., BOND, R.A. & LEE, M. (1995). Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci., 16, 10-13.
25. 4 receptors. Mol. Pharmacol., 31, 35-41.
26. MUNSON, P.J. & RODBARD, D. (1980). LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem., 107, 220-239.
27. MURPHY, R.C., HAMMASTRÖM, S. & SAMUELSSON, B. (1979). Leukotriene C: slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. U.S.A., 76, 4275-4279.
28. NICOSIA, S., CAPRA, V., RAGNINI, D., GIOVANAZZI, S., MEZZETTI, M., KEPPLER, D. & ROVATI, G.E. (1995). Receptors for Cysleukotrienes in human lung parenchyma: characterization by computer modelling and photoaffinity labelling of binding sites. In Advances Prostaglandin, Thromboxane, Leukotriene Research, ed. Samuelsson, B., Ramwell, P.W., Paoletti, R., Folco, G.C., Granström, E. & Nicosia, S. Vol. 23, pp. 267-269. New York: Raven Press.
29. O'SULLIVAN, B.P. & MONG, S. (1989). Binding of radiolabeled high affinity antagonist to leukotriene D4 receptor in guinea pig lung membranes: interconvertion of agonist-receptor binding affinity states. Mol. Pharmacol., 35, 795-802.
30. ROBERTSON, M.J., DOUGALL, I.G. HARPER, D., MCKECHNIE, K.C.W. & LEFF, P. (1994). Agonist-antagonist interactions at angiotensin receptor: application of a two state receptor model. Trends Pharmacol. Sci., 15, 364-369.
31. ROVATI, G.E. (1993). Rational design and analysis for ligand binding studies: tricks, tip and pitfalls. Pharmacol. Res., 28, 277-299.
32. 3H-ICI 198,615 in human lung parenchyma. Biochem. Pharmacol., 44, 1411-1415.
33. 4 in membranes from human lung. Biochem. Pharmacol., 34, 2831-2837.
34. ROVATI, G.E., RABIN, D. & MUNSON, P.J. (1991). Analysis, design and optimization of ligand binding experiments. In Horizon in Endocrinology. Vol II. ed. Maggi, M. & Greenen, E.V. pp. 155-167. New York: Serono Symposia Publication from Raven Press.
35. max in ligand binding experiments. (II. Simultaneous analysis of homologous and heterologous competition curves, blocking and 'multiligand' experiments). Anal. Biochem., 184, 172-183.
36. SAMUELSSON, B. (1983). Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 220, 568-575.
37. 4 induce transmembrane signaling in human epithelial cells. J. Biol. Chem., 265, 20976-20981.
38. SOK, D.E., PAI, J.K., ATRACHE, V. & SIH, C.J. (1980). Characterization of slow reacting substances (SRSs) of rat basophilic leukemia (RBL-1) cells: effect of cysteine on SRS prophile. Proc. Natl. Acad. Sci. U.S.A., 77, 6481-6485.
39. THIEN, F.C.K. & WALTERS, E.H. (1995). Eicosanoids and asthma: an update. Prostaglandins Leukotrienes Essent. Fatty Acids, 52, 271-288.
40. VIGANÒ, T. CRIVELLARI, M.T., MEZZETTI, M. & FOLCO, G.C. (1990). Preparation of human and animal lung tissue for eicosanoid research. In Methods of Enzymology. ed. Murphy, R.C. & Fitzpatrick, F.A. Vol. 184, pp. 621-628. San Diego: Academic Press, Inc.
41. 4. Med. Chem. Res., 1, 195-200.
42. 4 with special emphasis on CGP 45715A. Drugs of the Future, 16, 827-843.
43. VON SPRECHER, A., GERSPACHER, M., BECK, A., ANDERSON, G.P., NIEDERHAUSER, U., SUBRAMANIAN, N., BALL, H.A., GENTSCH, C., VASSOUT, A., FELNER, A., BITTIGER, H., HAUSER, K., GIESE, K., KRAETZ, J. & BRAY, M.A. (1997). CGP 57698: A simple, highly potent peptidoleukotriene (pLT) antagonist of the quinoline type. In Advances Prostaglandin Thromboxane Leukotriene Research, (in press).
44. VON SPRECHER, A., GERSPACHER, M., BECK, A., KIMMEL, S., WIESTNER, H.R., ANDERSON, G.P., NIEDERHAUSER, U., SUBRAMANIAN, N. & BRAY, M.A. (1996). CGP 57698: a simple, highly potent peptidoleukotriene (pLT) antagonist of the quinoline type. Prostaglandins Leukotrienes Essent. Fatty Acid, 55, P27.
45. 4 receptor solubilized in an active form. J. Biol. Chem., 265, 21237-21241.